United States Patent 8,163,725: Claim Scope, Expiration, Orange Book Relevance, and Competitive Patent Landscape

U.S. Patent No. 8,163,725 protects specific topical gel vehicles containing methylparaben, a second preservative, carbomer, polyols, water, and controlled pH. Its broadest commercial relevance is the formulation layer rather than the active ingredient alone. The patent also covers topical compositions containing alpha-adrenergic receptor agonists, but its method claims use a narrower closed list that does not expressly include brimonidine.

The patent issued on April 24, 2012, from an application claiming priority to a 2007 filing. Its projected statutory expiration is August 31, 2027, subject to any patent-term adjustment or disclaimer shown in the official patent record. The claims create potential formulation-based barriers for generic or follow-on topical alpha-adrenergic products that use the specified excipient system.

What does U.S. Patent 8,163,725 protect?

The patent has three claim groups:

Composition claims directed to a broad topical gel vehicle.
Narrower composition claims directed to propylene glycol and glycerol.
Method claims directed to topical treatment or prevention of listed skin disorders.

The independent claims are claims 1, 9, 15, and 17.

Claim	Claim type	Principal subject matter
1	Composition	Methylparaben, second preservative, carbomer, total polyol, water, and pH limitation
9	Composition	Methylparaben, specified preservative, carbomer, propylene glycol, glycerol, water, and sodium hydroxide-adjusted pH
15	Method	Administration of claim 1 composition containing a listed alpha-adrenergic agonist
17	Method	Administration of claim 9 composition containing a listed alpha-adrenergic agonist

Claims 2-8 depend from claim 1. Claims 10-14 depend from claim 9. Claims 16 and 18 narrow the skin-disorder indications in claims 15 and 17.

The use of “comprising” makes the composition claims open-ended. A product can contain additional excipients and still fall within the claims if every required limitation is present.

What are the required elements of claim 1?

Claim 1 requires all of the following:

Limitation	Claimed range or requirement
Methylparaben	0.05% to 0.20% by weight
Second preservative	Required, but not limited to the specific list in claim 8
Carbomer	0.80% to 1.50% by weight
Total polyol	9.0% to 13.0% by weight
Water	Purified water
pH	4.5 to 7.5
Conditional relationship	If methylparaben exceeds 0.15%, carbomer must be below 1.25%

The conditional limitation is commercially important. A formulation containing 0.16% methylparaben and 1.30% carbomer would fall outside claim 1 because the carbomer concentration is not below 1.25%. A formulation containing 0.15% methylparaben and 1.30% carbomer would not trigger the “greater than 0.15%” condition, assuming the other limitations are met.

The claim does not require an active pharmaceutical ingredient. A preservative-carbomer-polyol gel vehicle can therefore meet claim 1 even without an alpha-adrenergic agonist.

What formulations are protected by claim 9?

Claim 9 is narrower than claim 1 but more specific in its excipient architecture. It requires:

0.05% to 0.15% methylparaben;
a second preservative selected from sodium benzoate, phenoxyethanol, benzyl alcohol, imidazolidinyl urea, and diazolidinyl urea;
0.80% to 1.50% carbomer;
4.5% to 6.5% propylene glycol;
4.5% to 6.5% glycerol;
purified water; and
a pH of 5.0 to 6.5 adjusted with an adequate amount of aqueous sodium hydroxide.

Claim 9 does not expressly require a separately stated “total polyol” limitation. The propylene glycol and glycerol ranges collectively produce 9.0% to 13.0% polyol, but infringement would be assessed against the individual limitations in claim 9 rather than by treating the claim as if it repeated claim 1.

Claim 10 adds phenoxyethanol at more than 0.3% by weight. Claims 11 and 12 add titanium dioxide and an alpha-adrenergic agonist, respectively.

How do the dependent claims narrow the patent?

Claim	Added limitation
2	First polyol at approximately 4.5%-6.5%
3	Alpha-adrenergic receptor agonist
4	Alpha-1 or alpha-2 agonist
5	Closed list of eight agonists
6	0.04%-0.08% water-dispersible titanium dioxide
7	Carbomer 934P, 974P, or 980
8	Closed list of five second preservatives
10	Phenoxyethanol above 0.3%
11	0.04%-0.08% water-dispersible titanium dioxide
12	Alpha-adrenergic receptor agonist
13	Alpha-1 or alpha-2 agonist
14	Closed list of eight agonists
16	Specific skin disorders or symptoms
18	Specific skin disorders or symptoms

Claims 5 and 14 list oxymetazoline, phenylephrine, methoxyamine, tetrahydrozoline, naphazoline, xylometazoline, epinephrine, and norepinephrine. Brimonidine is not included in those closed lists.

That omission does not remove brimonidine from the broader composition claims. Claim 3 recites an alpha-adrenergic receptor agonist without limiting the claim to the list in claim 5. A brimonidine-containing composition could therefore be evaluated against claim 3, provided the underlying claim 1 formulation limitations are met. Claims 15 and 17 are narrower because they require an agonist selected from the expressly listed compounds.

Does the patent cover Mirvaso or brimonidine formulations?

The patent can be relevant to brimonidine formulations at the composition-claim level, but the method claims are materially narrower.

Composition claims

Claims 3, 4, and 12-13 can reach a formulation containing brimonidine because they recite an alpha-adrenergic receptor agonist or an alpha-1 or alpha-2 agonist without expressly excluding brimonidine. The formulation must also satisfy the applicable methylparaben, preservative, carbomer, polyol, water, and pH requirements.

Method claims

Claims 15 and 17 require an agonist selected from the eight named compounds. Brimonidine is absent from that Markush group. A method of treating rosacea with brimonidine would not literally satisfy the agonist limitation as written, although other infringement theories would depend on claim construction, prosecution history, and the facts of the product and use.

Commercial relevance

Mirvaso is a brimonidine tartrate topical gel approved by the FDA for the topical treatment of persistent facial erythema associated with rosacea. The FDA-approved product therefore provides a relevant commercial comparator for the vehicle claims, but the patent’s claim language must be compared with the approved formulation rather than the product name alone (FDA, 2013).

When does U.S. Patent 8,163,725 lose exclusivity?

The patent’s expected expiration date is August 31, 2027, based on its earliest claimed priority date. The effective date must be confirmed against the USPTO patent record, including any patent-term adjustment, terminal disclaimer, reexamination certificate, or other post-grant event.

Event	Date
Earliest claimed priority	August 31, 2007
Patent issued	April 24, 2012
Estimated 20-year expiration	August 31, 2027

Patent expiration does not automatically eliminate every barrier to generic entry. Separate patents may cover:

the active ingredient;
a particular salt or concentration;
a dosing regimen;
a therapeutic indication;
a manufacturing process;
a container or dispenser;
a different formulation;
or an FDA-listed method of use.

A generic applicant would need to assess the complete Orange Book listing and patent estate for the relevant reference-listed drug.

What is the Orange Book status of the patent?

U.S. Patent 8,163,725 has been associated in public pharmaceutical patent records with topical alpha-adrenergic products, including the formulation and vehicle technology relevant to rosacea products. Orange Book relevance depends on the specific NDA and product to which the patent is listed.

For a 505(j) applicant, the key questions are:

Whether the patent is listed against the selected reference-listed drug.
Whether the applicant’s ANDA product contains the claimed formulation.
Whether the applicant certifies under Paragraph I, II, III, or IV.
Whether the patent is a method-of-use patent that can be addressed through a section viii statement.
Whether the reference product has additional unexpired formulation or use patents.

A Paragraph IV certification asserting invalidity, unenforceability, or noninfringement can trigger patent litigation under the Hatch-Waxman Act. A successful Paragraph IV challenge can support approval before patent expiration. A Paragraph III certification generally defers approval until the relevant patent expires.

The patent claims supplied here are primarily formulation claims. That makes a simple section viii carve-out less likely where the ANDA product itself practices the claimed vehicle, even if the applicant omits a patented indication.

What generic entry risks exist?

The highest risk arises where a proposed product reproduces the excipient architecture rather than merely using the same active ingredient.

High-risk formulation profile

A product presents a strong literal-infringement risk if it contains:

methylparaben between 0.05% and 0.15%;
phenoxyethanol above 0.3%;
carbomer between 0.80% and 1.50%;
propylene glycol and glycerol each between 4.5% and 6.5%;
purified water; and
pH between 5.0 and 6.5 adjusted with sodium hydroxide.

That profile maps directly onto claim 9 and potentially claims 10-13.

Moderate-risk formulation profile

Risk remains substantial for a product containing:

methylparaben between 0.05% and 0.20%;
another preservative;
carbomer in the claimed range;
total polyol within 9.0%-13.0%; and
pH within 4.5-7.5.

The product may fall within claim 1 even if it uses a different alpha agonist or additional excipients.

Lower-risk design-around profile

Potential design-around approaches include changing one or more critical parameters:

methylparaben below 0.05% or above 0.20%;
carbomer below 0.80% or above 1.50%;
total polyol outside 9.0%-13.0%;
pH outside 4.5-7.5;
replacing the claimed preservative system;
using a non-carbomer gelling polymer;
replacing the propylene glycol-glycerol combination;
avoiding the sodium hydroxide-adjusted pH architecture of claim 9.

A design-around must be tested against the doctrine of equivalents and against other patents. Moving a concentration marginally outside a claimed range does not eliminate litigation risk where the formulation performs substantially the same function in substantially the same way.

How strong is the patent estate?

The patent has meaningful formulation coverage but limited active-ingredient specificity.

Strengths

Claim 1 covers a broad vehicle without requiring an active ingredient.
Claim 9 captures a commercially plausible propylene glycol-glycerol gel.
The claims combine composition ranges with pH and preservative limitations, making simple ingredient substitution less effective.
Claims 3 and 12 can extend composition coverage to alpha-adrenergic products beyond the named agonists.
The open “comprising” language permits additional excipients.

Weaknesses and potential attack points

The formulation is built from conventional pharmaceutical excipients.
The broad composition claims may face obviousness arguments based on known preserved carbomer gels and polyol-containing topical vehicles.
The phrase “total polyol” may create measurement and claim-construction issues where multiple polyols or multifunctional ingredients are used.
“Adequate amount” of sodium hydroxide in claim 9 may be challenged for indefiniteness or interpreted in view of the specification.
“Water dispersible form” of titanium dioxide may create scope questions.
The closed agonist lists in claims 5, 14, 15, and 17 exclude brimonidine expressly.
Method claims 15-18 depend on treatment or prevention of a broad collection of disorders, which may raise written-description, enablement, or divided-infringement issues depending on the accused product and labeling.

Which companies are challenging the patent?

The claims provided do not identify any Paragraph IV filer, district-court action, inter partes review, post-grant review, or settlement agreement involving U.S. Patent 8,163,725. Patent litigation and settlement status must be evaluated separately from the patent text and cannot be inferred from the issued claims.

The relevant competitive group includes:

the NDA holder and successor owners of the branded topical alpha-adrenergic product;
ANDA applicants developing generic topical gels;
companies developing alternative carbomer or non-carbomer vehicles;
sponsors of rosacea and facial-erythema products using brimonidine, oxymetazoline, or related vasoconstrictors; and
manufacturers using different preservative and polyol systems.

Does biosimilar risk apply?

No. Biosimilar regulation is not the relevant pathway because this patent covers a topical small-molecule composition and treatment method, not a biologic product. The principal regulatory pathway for a copy of an applicable topical drug product is an ANDA under section 505(j), although a 505(b)(2) application may be used for certain formulation, indication, or clinical-bridging strategies.

What manufacturing and geographic barriers remain?

The patent is a U.S. right. It does not directly block manufacture, sale, or use outside the United States. Separate national patent families must be reviewed in Europe, Canada, Japan, China, and other target markets.

Manufacturing risk can remain even where a finished product is designed around the patent. The sponsor must assess:

carbomer grade and neutralization behavior;
preservative solubility and compatibility;
polyol concentration and water activity;
pH adjustment sequence;
titanium dioxide dispersion, where applicable;
microbial preservative effectiveness;
viscosity and rheology;
batch-to-batch concentration controls; and
analytical methods for methylparaben, preservatives, polyols, and active ingredient.

A manufacturing process patent or trade secret may create a separate barrier even if the finished composition does not infringe claim 1 or claim 9.

Key Takeaways

U.S. Patent 8,163,725 is primarily a topical gel formulation patent.
Claim 1 broadly covers methylparaben, a second preservative, carbomer, 9%-13% total polyol, purified water, and pH 4.5-7.5.
Claim 9 is a narrower but commercially significant formulation claim covering propylene glycol, glycerol, specified preservatives, carbomer, and sodium hydroxide-adjusted pH.
Composition claims can reach an alpha-adrenergic agonist not named in the dependent Markush claims, including potentially brimonidine.
Method claims 15 and 17 use closed agonist lists that do not expressly include brimonidine.
The projected patent expiration is August 31, 2027, subject to official term calculations.
The principal generic risk is literal infringement by reproducing the claimed excipient ranges and pH architecture.
Biosimilar analysis is not applicable.
A complete launch assessment requires review of the full Orange Book listing and any additional formulation, active-ingredient, method-of-use, and manufacturing patents associated with the relevant reference product.

FAQs

Is U.S. Patent 8,163,725 an active-ingredient patent?

No. Its central protection is directed to a topical gel vehicle and, in dependent claims, formulations containing alpha-adrenergic receptor agonists.

Can a formulation with brimonidine infringe claim 3?

Yes, potentially. Claim 3 broadly recites an alpha-adrenergic receptor agonist and does not limit the composition to the eight compounds listed in claim 5. All claim 1 limitations must also be satisfied.

Does claim 9 require phenoxyethanol?

No. Claim 9 permits sodium benzoate, phenoxyethanol, benzyl alcohol, imidazolidinyl urea, or diazolidinyl urea. Claim 10 narrows the formulation to phenoxyethanol above 0.3%.

Can changing the carbomer grade avoid the patent?

Not necessarily. Claim 1 covers carbomer generally. Claim 7 narrows the claim to carbomer 934P, 974P, or 980, but avoiding those grades does not by itself avoid independent claim 1 or claim 9.

Is a generic sponsor required to challenge the patent under Paragraph IV?

Only if the patent is listed for the relevant reference product and remains an obstacle to approval. The applicant may use another certification or statement depending on the patent type, listing status, expiration date, and the proposed product’s formulation and labeling.

References

United States Patent and Trademark Office. (2012). U.S. Patent No. 8,163,725, topical gel compositions and methods of use thereof. Washington, DC: U.S. Department of Commerce.
U.S. Food and Drug Administration. (2013). Mirvaso (brimonidine tartrate) topical gel, 0.33%: Prescribing information. Silver Spring, MD: U.S. Department of Health and Human Services.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Silver Spring, MD: U.S. Department of Health and Human Services.
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations, patent and exclusivity information. Silver Spring, MD: U.S. Department of Health and Human Services.
U.S. Patent and Trademark Office. (2024). Manual of Patent Examining Procedure. Washington, DC: U.S. Department of Commerce.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Galderma Labs Lp	MIRVASO	brimonidine tartrate	GEL;TOPICAL	204708-001	Aug 23, 2013	AB	RX	Yes	Yes	8,163,725	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	083651	⤷ Start Trial
Australia	2011317554	⤷ Start Trial
Brazil	112013009578	⤷ Start Trial
Canada	2814952	⤷ Start Trial
China	103298451	⤷ Start Trial
Cyprus	1115683	⤷ Start Trial
Denmark	2444068	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,163,725

Which drugs does patent 8,163,725 protect, and when does it expire?

Summary for Patent: 8,163,725